News Channels

28 Aug 2018 Tetraphase Pharmaceuticals Announces FDA Approval of XERAVA™ (Eravacycline) for Complicated Intra-Abdominal Infections (cIAI)
28 Aug 2018 Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Europe for the Treatment of Mucopolysaccharidosis VII
28 Aug 2018 Janssen Announces Results from MARINER and COMMANDER HF Studies
28 Aug 2018 LifeMax Acquires Worldwide Right to Clinical Stage Orphan Asset
28 Aug 2018 Akcea and Ionis Receive Complete Response Letter for WAYLIVRA from FDA
28 Aug 2018 Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets
27 Aug 2018 CENTOGENE and Evotec Sign Global Strategic Partnership on Drug Discovery Projects in Rare Genetic Diseases
27 Aug 2018 Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy
27 Aug 2018 Amgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone
27 Aug 2018 A Specific Active ImmunoTherapy (SAIT) to control cholesterol levels in blood
27 Aug 2018 BeiGene Announces Acceptance of its First New Drug Application for Zanubrutinib in Relapsed/Refractory Mantle Cell Lymphoma by China Drug Administration
27 Aug 2018 Sienna Biopharmaceuticals Announces Results from First-in-Human Study of SNA-125 in Psoriasis and Continued Progression to Phase 2
27 Aug 2018 Bayer submits European marketing authorization application for larotrectinib for the treatment of TRK fusion cancer
27 Aug 2018 AbbVie Announces IMBRUVICA® (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer
27 Aug 2018 Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)
27 Aug 2018 Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Results Presented as Late-Breaking Data at the ESC Congress 2018
26 Aug 2018 uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
26 Aug 2018 Zai Lab Elects to Discontinue Development of ZL-3101 (Fugan) for Atopic Dermatitis
26 Aug 2018 Ozempic® consistently reduced the risk of major cardiovascular events across type 2 diabetes populations at high CV risk regardless of prior CV events at baseline
26 Aug 2018 Novaremed announces that it has raised CHF 6 million to prepare for a Phase 2b clinical study in Diabetic Neuropathic Pain

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up